The test's developer, California-based molecular diagnostics company Cepheid, said on Saturday it had received an emergency use authorization from the FDA for the test, which will be used primarily in hospitals and emergency rooms. The FDA confirmed its approval in a separate statement. It said the company intends to roll out the availability of its testing by March 30.
from Yahoo News - Latest News & Headlines https://ift.tt/2xb03TX
No comments:
Post a Comment